Cogent Biosciences (COGT) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Cogent Biosciences (COGT) over the past year, gaining 363.7% versus a gain of 93.1%. Over five years, COGT leads with a +225.5% price change compared with +34.8% for TWST. Twist Bioscience is the larger company by market cap ($10.08 billion vs $5.22 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | TWST |
|---|---|---|
| Share price | $30.08 | $152.05 |
| Market cap | $5.22B | $10.08B |
| 1-day change | -0.20% | -2.31% |
| YTD return | -15.32% | +379.35% |
| 1-year return | +93.07% | +363.71% |
| 5-year return | +225.54% | +34.80% |
| EPS (TTM) | $-2.16 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.57M |
| Revenue growth (YoY) | — | +20.32% |
| Net income (latest FY) | $-328.94M | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | — | -36.18% |
| Net margin | — | -20.63% |
| 52-week high | $43.73 | $219.71 |
| 52-week low | $13.78 | $23.30 |
| Distance from 52-week high | -31.21% | -30.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +85.57% | -1.13% |
| Average volume | 1.90M | 2.04M |
| Shares outstanding | 173.52M | 66.30M |
| Employees | 258 | 979 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed COGT by 270.6 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Healthcare · Biotechnology · 258 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Healthcare · Biotechnology · 979 employees
COGT vs TWST FAQ
Which is bigger, Cogent Biosciences or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.08B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or TWST?
TWST returned +363.71% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.